Fate Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, FATE, Fate Therapeutics Inc, priceseries

Fate Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
32.79
Close
31.86
High
33.95
Low
31.42
Previous Close
32.47
Daily Price Gain
-0.61
YTD High
60.43
YTD High Date
Jan 3, 2022
YTD Low
30.14
YTD Low Date
Feb 24, 2022
YTD Price Change
-28.42
YTD Gain
-47.15%
52 Week High
98.28
52 Week High Date
Mar 11, 2021
52 Week Low
30.14
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-47.30
52 Week Gain
-59.75%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
2.94
Mar 7. 2017
3.98
17 Trading Days
35.44%
Link
LONG
Aug 28. 2017
3.22
Sep 20. 2017
4.14
16 Trading Days
28.65%
Link
LONG
Dec 20. 2017
4.51
Jan 16. 2018
6.60
16 Trading Days
46.32%
Link
LONG
Jan 18. 2018
7.18
Feb 2. 2018
8.79
11 Trading Days
22.42%
Link
LONG
Feb 16. 2018
8.76
Mar 13. 2018
12.14
16 Trading Days
38.64%
Link
LONG
Apr 10. 2018
10.06
Apr 27. 2018
11.29
13 Trading Days
12.18%
Link
LONG
May 16. 2018
10.18
May 30. 2018
11.01
9 Trading Days
8.12%
Link
LONG
Jun 12. 2018
11.77
Jun 15. 2018
12.56
3 Trading Days
6.75%
Link
LONG
Sep 18. 2018
12.20
Oct 5. 2018
15.15
13 Trading Days
24.18%
Link
LONG
Nov 26. 2018
13.49
Dec 14. 2018
15.35
13 Trading Days
13.82%
Link
LONG
Jan 4. 2019
14.78
Jan 18. 2019
15.69
10 Trading Days
6.14%
Link
LONG
Mar 7. 2019
16.11
Mar 22. 2019
17.10
11 Trading Days
6.12%
Link
LONG
May 14. 2019
17.28
May 23. 2019
18.36
7 Trading Days
6.28%
Link
LONG
Jun 14. 2019
17.83
Jun 24. 2019
19.09
6 Trading Days
7.09%
Link
LONG
Jan 6. 2020
19.81
Jan 27. 2020
23.35
14 Trading Days
17.86%
Link
LONG
Feb 10. 2020
26.73
Feb 27. 2020
28.78
12 Trading Days
7.69%
Link
LONG
Apr 8. 2020
25.63
Apr 28. 2020
28.31
13 Trading Days
10.47%
Link
LONG
May 8. 2020
28.84
May 12. 2020
30.45
2 Trading Days
5.57%
Link
LONG
May 15. 2020
28.45
Jun 1. 2020
31.96
10 Trading Days
12.33%
Link
LONG
Sep 11. 2020
33.56
Sep 23. 2020
36.48
8 Trading Days
8.71%
Link
LONG
Nov 20. 2020
52.65
Dec 29. 2020
92.49
25 Trading Days
75.66%
Link
LONG
Jan 6. 2021
99.78
Jan 20. 2021
110.49
9 Trading Days
10.73%
Link
LONG
Jun 7. 2021
77.00
Jun 16. 2021
80.93
7 Trading Days
5.11%
Link
Company Information
Stock Symbol
FATE
Exchange
NasdaqGM
Company URL
http://www.fatetherapeutics.com
Company Phone
858.875.1803
CEO
J. Scott Wolchko
Headquarters
California
Business Address
3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434316
About

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. Fate Therapeutics was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading